Jacopo Pigozzo

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

Célèste Lebbé, Nicolás Meyer, Laurent Mortier et al. · Journal of Clinical Oncology · 2019 · 398 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

Pier Francesco Ferrucci, Paolo A. Ascierto, Jacopo Pigozzo et al. · Annals of Oncology · 2016 · 395 citations · Full text

Medicine, Hematology, Oncology +17

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade

Sara Valpione, Sandro Pasquali, L Campana et al. · Journal of Translational Medicine · 2018 · 199 citations · Full text

Life Sciences, Immunology, Oncology +17

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

Paolo A. Ascierto, Ester Simeone, Vanna Chiarion‐Sileni et al. · Journal of Translational Medicine · 2014 · 163 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio et al. · Journal of Clinical Oncology · 2022 · 162 citations · Full text

Medicine, Oncology, Pharmacotherapy +17